Introduction: Alzheimer's disease (AD) is a world-wide health problem with implications for
an increasing number of people and countries. Populations suffering from AD financially …

Available symptomatic therapies for the treatment of Alzheimer's disease (AD) have been
based on known neurotransmitter dysfunctions associated with the illness. The second …

Introduction: Currently, five pharmacotherapeutic options are available to treat Alzheimer's
disease: memantine; the three cholinesterase inhibitors donepezil, galantamine, and …

Alzheimer's disease (AD) is an age-related neurodegenerative disease that affects
approximately 4.5 million people in the United States. The mainstays of current …

Background: The role of currently available drugs for Alzheimer's disease (AD) has been
controversial, with some national formularies restricting their use, and health economists …

Background: Randomized clinical trials have evaluated the efficacy of acetylcholinesterase
inhibitors (AChE-Is) and memantine across a wide range of Alzheimer's disease (AD) …

Alzheimer's disease (AD) is the most common cause of memory impairment and dementia in
the elderly. AD is pathologically characterized by extracellular deposits of beta-amyloid (Aβ) …

Introduction: To date, pharmacological treatment of Alzheimer's disease (AD) includes
Acetylcholinesterase Inhibitors (AChEIs) for mild-to-moderate AD, and memantine for …

Alzheimer's disease (AD) is the most common neurodegenerative disorder and the most
prevalent cause of dementia with ageing. Pharmacological treatment of AD is based on the …

Background Cholinesterase inhibitors and memantine have been approved for
management of Alzheimer's disease (AD), but there has been no consensus about the …